Ding Cao, Menghao Wang, Junhua Gong, Sidong Wei, Jianping Gong, Jinzheng Li – 10 February 2017 – Vascular endothelial growth factor (VEGF) promotes angiogenesis in vivo. We hypothesized that exogenous delivery of VEGF prior to bone marrow–derived endothelial precursor cell (EPC) transplantation may improve orthotopic liver transplantation (OLT)–induced hepatic ischemia/reperfusion injury (HIRI).

Elena Fernandez‐Sevilla, Marc‐Antoine Allard, Jasmijn Selten, Nicolas Golse, Eric Vibert, Antonio Sa Cunha, Daniel Cherqui, Denis Castaing, René Adam – 10 February 2017 – Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is widely considered as a terminal condition. Therefore, the role of surgery is uncertain in this case. The purpose of this study was to identify the prognostic factors of survival after post‐LT HCC recurrence and to evaluate the impact of surgery in this setting.

Sang Gyune Kim, Joseph J. Larson, Ji Sung Lee, Terry M. Therneau, W. Ray Kim – 10 February 2017 – Nonselective beta‐blockers (NSBBs) have played an important role in the prevention of portal hypertensive bleeding in patients with cirrhosis. However, recent studies have suggested that NSBBs may be harmful in some patients with end‐stage liver disease. The purpose of this article is to evaluate the association between use of NSBB and the incidence of acute kidney injury (AKI). We conducted a nested case‐control study in a cohort of liver transplant wait‐list registrants.

John R. Senior – 9 February 2017

Solène Denolly, François‐Loïc Cosset – 8 February 2017

Cybele Lara R. Abad, Brian D. Lahr, Raymund R. Razonable – 8 February 2017 – The epidemiology of infections after living donor liver transplantation (LDLT) is limited. We aimed to study the epidemiology and risk factors of infections after LDLT. The medical records of 223 adult patients who underwent LDLT from January 1, 2000 to August 31, 2015 were reviewed for all infections occurring up to 1 year. We estimated the cumulative incidence of infection using the Kaplan‐Meier product limit method. Risk factors were analyzed with time‐dependent Cox regression modeling.

Marcin Krawczyk, Monika Rau, Frank Grünhage, Jörn M. Schattenberg, Heike Bantel, Anita Pathil, Münevver Demir, Johannes Kluwe, Tobias Boettler, Andreas Geier, Frank Lammert, NAFLD Clinical Study Group (NAFLD CSG) – 8 February 2017

Benjamin Cadier, Julie Bulsei, Pierre Nahon, Olivier Seror, Alexis Laurent, Isabelle Rosa, Richard Layese, Charlotte Costentin, Carole Cagnot, Isabelle Durand‐Zaleski, Karine Chevreul, the ANRS CO12 CirVir and CHANGH groups – 8 February 2017 – Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. Patients outside clinical trials seldom benefit from evidence‐based monitoring. The objective of this study was to estimate the cost‐effectiveness of complying with HCC screening guidelines.

Carlos Fernández Carrillo, Sabela Lens, Elba Llop, Juan Manuel Pascasio, Javier Crespo, Juan Arenas, Inmaculada Fernández, Carme Baliellas, José Antonio Carrión, Manuel de la Mata, Maria Buti, Lluís Castells, Agustín Albillos, Manuel Romero, Juan Turnes, Clara Pons, José María Moreno‐Planas, José Javier Moreno‐Palomares, Conrado Fernández‐Rodriguez, Javier García‐Samaniego, Martín Prieto, Miguel Fernández Bermejo, Javier Salmerón, Ester Badia, Magdalena Salcedo, José Ignacio Herrero, Rafael Granados, Michel Blé, Zoe Mariño, José Luis Calleja – 7 February 2017 – Direct‐acting antiviral agent

Sebastian Mueller, Pierre Nahon, Vanessa Rausch, Tessa Peccerella, Ines Silva, Eray Yagmur, Beate K. Straub, Carolin Lackner, Helmut K. Seitz, Pierre Rufat, Angela Sutton, Heike Bantel, Thomas Longerich – 7 February 2017 – Noninvasive assessment of disease activity in patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) is still unsettled, but essential for the evaluation of disease progression.